全文获取类型
收费全文 | 122894篇 |
免费 | 41316篇 |
国内免费 | 167篇 |
专业分类
耳鼻咽喉 | 1833篇 |
儿科学 | 5249篇 |
妇产科学 | 526篇 |
基础医学 | 25034篇 |
口腔科学 | 6703篇 |
临床医学 | 15008篇 |
内科学 | 27196篇 |
皮肤病学 | 4363篇 |
神经病学 | 20808篇 |
特种医学 | 6168篇 |
外科学 | 15376篇 |
综合类 | 1224篇 |
一般理论 | 10篇 |
预防医学 | 8655篇 |
眼科学 | 1410篇 |
药学 | 10119篇 |
10篇 | |
中国医学 | 2198篇 |
肿瘤学 | 12487篇 |
出版年
2024年 | 55篇 |
2023年 | 264篇 |
2022年 | 505篇 |
2021年 | 2209篇 |
2020年 | 6487篇 |
2019年 | 11750篇 |
2018年 | 11279篇 |
2017年 | 12516篇 |
2016年 | 11621篇 |
2015年 | 11535篇 |
2014年 | 11547篇 |
2013年 | 11713篇 |
2012年 | 10789篇 |
2011年 | 10713篇 |
2010年 | 9257篇 |
2009年 | 5782篇 |
2008年 | 6315篇 |
2007年 | 4665篇 |
2006年 | 4470篇 |
2005年 | 4183篇 |
2004年 | 4033篇 |
2003年 | 3679篇 |
2002年 | 3462篇 |
2001年 | 2637篇 |
2000年 | 1452篇 |
1999年 | 326篇 |
1998年 | 87篇 |
1997年 | 99篇 |
1996年 | 73篇 |
1995年 | 75篇 |
1994年 | 78篇 |
1993年 | 68篇 |
1992年 | 54篇 |
1991年 | 69篇 |
1990年 | 75篇 |
1989年 | 50篇 |
1988年 | 40篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 45篇 |
1984年 | 46篇 |
1983年 | 25篇 |
1982年 | 33篇 |
1981年 | 22篇 |
1980年 | 31篇 |
1979年 | 19篇 |
1978年 | 18篇 |
1977年 | 25篇 |
1976年 | 9篇 |
1974年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
Spectrum and immunophenotyping of 653 patients with B‐cell chronic lymphoproliferative disorders in China: A single‐centre analysis 下载免费PDF全文
Yi Miao Lei Cao Qian Sun Xiao‐Tong Li Yan Wang Chun Qiao Li Wang Rong Wang Hai‐Rong Qiu Wei Xu Jian‐Yong Li Yu‐Jie Wu Lei Fan 《Hematological oncology》2018,36(1):121-127
The incidence of B‐cell chronic lymphoproliferative disorders (B‐CLPDs) is significantly lower in China than that in western countries. There have been studies involving small cohorts with conflicting results regarding the spectrum of B‐CLPDs in China, and the types and immunophenotyping of B‐CLPDs in China remain largely unexplored. We conducted a retrospective analysis of 653 cases of B‐CLPDs seen in our centre from 2011 to 2015. Four‐colour flow cytometry was used to determine the expression of each immunological marker, and the diagnostic values of the immunological markers were also investigated. Chronic lymphocytic leukaemia (CLL) was the most common type of B‐CLPD, which was consistent with that in west countries. However, the proportions of CLL (55.9%), follicular lymphoma (2.6%), and hairy cell leukaemia (0.2%) were lower, while the proportion of lymphoplasmacytic lymphoma/WaldenstrÖm macroglobulinaemia (5.4%) was higher in China, as compared with western countries. With respect to immunophenotypic characteristics, CD23 (31.7%) was more frequently expressed in mantle cell lymphoma (MCL) in our cohort than that in western countries. Immunophenotyping was useful in differentiating MCL from CLL or B‐cell prolymphocytic leukaemia and lymphoplasmacytic lymphoma/WaldenstrÖm macroglobulinaemia from splenic marginal zone lymphoma. CD200 was of better diagnostic performance (accuracy: 94.6%) in differentiating CLL from MCL compared with CD23 (accuracy: 93.3%). Some cases of B‐CPLDs, however, had no definite diagnoses, which were diagnosed as CD5+B‐CPLDs unclassified (7.7%) and CD5?B‐CPLDs unclassified (15.8%). This is the largest study that systematically explores the spectrum and immunophenotyping of B‐CLPDs in Asia, confirming that spectrum of B‐CLPDs in China was different from that in western countries. The immunophenotypic features of B‐CLPDs were similar between China and western countries, although a few disparities exist. Cases with no definite diagnoses warrant further studies in the future. 相似文献
993.
Jiao Peng Julia Y. Tsang Derek H. Ho Ruizhong Zhang Haitao Xiao Daxu Li Jiang Zhu Fenghua Wang Zhaoxiang Bian Vincent C. Lui Aimin Xu Paul K. Tam Jonathan R. Lamb Huimin Xia Yan Chen 《International journal of cancer. Journal international du cancer》2015,137(4):848-858
The plasticity of macrophages with selective functional phenotypes partially arises in respective to their microenvironment. Tumor‐associated macrophages (TAMs) may promote disease progression with tumor specific manner. Here we report that in pediatric malignant soft‐tissue tumors, the presence of TAMs and expression of adiponectin (APN) are heterogeneous. Both APN and TAMs had high expression in rhabdomyosarcoma, especially in the malignant subtype, alveolar rhabdomyosarcoma. To investigate the mode of action of APN on TAM activation, a murine MN/MCA1 sarcoma model was used. The Results revealed that exogenous APN had no effect on MN/MCA1 proliferation but tumor size was markedly reduced in apn?/? mice versus WT controls. The accumulation of TAMs in apn?/? mice was also reduced which correlated to downregulated serum levels of MCP‐1. Likewise, TAMs in apn?/? mice exhibited a M1‐like phenotype, characterized by increase in MHC IIhigh population and M1 phenotypic markers, such as iNOS gene and serum TNF‐α accompanied by a decrease in M2 markers, namely YM1 gene and serum IL‐10. In addition, APN deficiency increased the number of CD4+ T cells, CD8+ T cells and NK cells in tumors and reduced tumor metastasis. The altered phenotype of TAMs in apn?/? mice was associated with a marked decrease in phospho‐p38 and treatment with a p38 MAPK inhibitor significantly reduced tumor size and increased MHC II expression on TAMs in WT mice, implying p38 MAPK signaling pathway may contribute to APN‐mediated TAM polarization. Collectively, our findings suggest that APN may have a potential role in regulating soft tissue sarcoma growth. 相似文献
994.
Solid cancer incidence among Chinese medical diagnostic x‐ray workers, 1950–1995: Estimation of radiation‐related risks 下载免费PDF全文
Zhijuan Sun Peter D. Inskip Jixian Wang Deukwoo Kwon Yongcheng Zhao Liangan Zhang Qin Wang Saijun Fan 《International journal of cancer. Journal international du cancer》2016,138(12):2875-2883
The objective of this study was to estimate solid cancer risk attributable to long‐term, fractionated occupational exposure to low doses of ionizing radiation. Based on cancer incidence for the period 1950–1995 in a cohort of 27,011 Chinese medical diagnostic X‐ray workers and a comparison cohort of 25,782 Chinese physicians who did not use X‐ray equipment in their work, we used Poisson regression to fit excess relative risk (ERR) and excess absolute risk (EAR) dose–response models for incidence of all solid cancers combined. Radiation dose reconstruction was based on a previously published method that relied on simulating measurements for multiple X‐ray machines, workplaces and working conditions, information about protective measures, including use of lead aprons, and work histories. The resulting model was used to estimate calendar year‐specific badge dose calibrated as personal dose equivalent (Sv). To obtain calendar year‐specific colon doses (Gy), we applied a standard organ conversion factor. A total of 1,643 cases of solid cancer were identified in 1.45 million person‐years of follow‐up. In both ERR and EAR models, a statistically significant radiation dose–response relationship was observed for solid cancers as a group. Averaged over both sexes, and using colon dose as the dose metric, the estimated ERR/Gy was 0.87 (95% CI: 0.48, 1.45), and the EAR was 22 per 104PY‐Gy (95% CI: 14, 32) at age 50. We obtained estimates of the ERR and EAR of solid cancers per unit dose that are compatible with those derived from other populations chronically exposed to low dose‐rate occupational or environmental radiation. 相似文献
995.
996.
Leandro E. Mainetti Xiaoning Zhe Jonathan Diedrich Allen D. Saliganan Won Jin Cho Michael L. Cher Elisabeth Heath Rafael Fridman Hyeong‐Reh Choi Kim R. Daniel Bonfil 《International journal of cancer. Journal international du cancer》2015,136(1):11-20
Loss of BRCA2 function stimulates prostate cancer (PCa) cell invasion and is associated with more aggressive and metastatic tumors in PCa patients. Concurrently, the receptor tyrosine kinase c‐kit is highly expressed in skeletal metastases of PCa patients and induced in PCa cells placed into the bone microenvironment in experimental models. However, the precise requirement of c‐kit for intraosseous growth of PCa and its relation to BRCA2 expression remain unexplored. Here, we show that c‐kit expression promotes migration and invasion of PCa cells. Alongside, we found that c‐kit expression in PCa cells parallels BRCA2 downregulation. Gene rescue experiments with human BRCA2 transgene in c‐kit‐transfected PCa cells resulted in reduction of c‐kit protein expression and migration and invasion, suggesting a functional significance of BRCA2 downregulation by c‐kit. The inverse association between c‐kit and BRCA2 gene expressions in PCa cells was confirmed using laser capture microdissection in experimental intraosseous tumors and bone metastases of PCa patients. Inhibition of bone‐induced c‐kit expression in PCa cells transduced with lentiviral short hairpin RNA reduced intraosseous tumor incidence and growth. Overall, our results provide evidence of a novel pathway that links bone‐induced c‐kit expression in PCa cells to BRCA2 downregulation and supports bone metastasis. 相似文献
997.
Thorsten Zenz Markus Kreuz Maxi Fuge Wolfram Klapper Heike Horn Annette M. Staiger Doris Winter Hanne Helfrich Jennifer Huellein Martin‐Leo Hansmann Harald Stein Alfred Feller Peter M?ller Norbert Schmitz Lorenz Trümper Markus Loeffler Reiner Siebert Andreas Rosenwald German Ott Michael Pfreundschuh Stephan Stilgenbauer for the German High‐Grade Non‐Hodgkin Lymphoma Study Group 《International journal of cancer. Journal international du cancer》2017,141(7):1381-1388
TP53 is mutated in 20–25% of aggressive B‐cell lymphoma (B‐NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current risk models in aggressive B‐NHL, we investigated TP53 gene mutations within the RICOVER‐60 trial. Of 1,222 elderly patients (aged 61–80 years) enrolled in the study and randomized to six or eight cycles of CHOP‐14 with or without Rituximab (NCT00052936), 265 patients were analyzed for TP53 mutations. TP53 mutations were demonstrated in 63 of 265 patients (23.8%). TP53 mutation was associated with higher LDH (65% vs. 37%; p < 0.001), higher international prognostic index‐Scores (IPI 4/5 27% vs. 12%; p = 0.025) and B‐symptoms (41% vs. 24%; p = 0.011). Patients with TP53 mutation were less likely to obtain a complete remission CR/CRu (CR unconfirmed) 61.9% (mut) vs. 79.7% (wt) (p = 0.007). TP53 mutations were associated with decreased event‐free (EFS), progression‐free (PFS) and overall survival (OS) (median observation time of 40.2 months): the 3 year EFS, PFS and OS were 42% (vs. 60%; p = 0.012), 42% (vs. 67.5%; p < 0.001) and 50% (vs. 76%; p < 0.001) for the TP53 mutation group. In a Cox proportional hazard analysis adjusting for IPI‐factors and treatment arms, TP53 mutation was shown to be an independent predictor of EFS (HR 1.5), PFS (HR 2.0) and OS (HR 2.3; p < 0.001). TP53 mutations are independent predictors of survival in untreated patients with aggressive CD20+ lymphoma. TP53 mutations should be considered for risk models in DLBCL and strategies to improve outcome for patients with mutant TP53 must be developed. 相似文献
998.
Therapeutic advances in BIG3‐PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer 下载免费PDF全文
Tetsuro Yoshimaru Masato Komatsu Yasuo Miyoshi Junko Honda Mitsunori Sasa Toyomasa Katagiri 《Cancer science》2015,106(5):550-558
Our previous studies demonstrated that specific inhibition of the BIG3‐PHB2 complex, which is a critical modulator in estrogen (E2) signaling, using ERAP, a dominant negative peptide inhibitor, leads to suppression of E2‐dependent estrogen receptor (ER) alpha activation through the reactivation of the tumor suppressive activity of PHB2. Here, we report that ERAP has significant suppressive effects against synergistic activation caused by the crosstalk between E2 and growth factors associated with intrinsic or acquired resistance to anti‐estrogen tamoxifen in breast cancer cells. Intrinsic PHB2 released from BIG3 by ERAP effectively disrupted each interaction of membrane‐associated ERα and insulin‐like growth factor 1 receptor beta (IGF‐1Rβ), EGFR, PI3K or human epidermal growth factor 2 (HER2) in the presence of E2 and the growth factors IGF or EGF, followed by inhibited the activation of IGF‐1Rβ, EGFR or HER2, and reduced Akt, MAPK and ERα phosphorylation levels, resulting in significant suppression of proliferation of ERα‐positive breast cancer cells in vitro and in vivo. More importantly, combined treatment with ERAP and tamoxifen led to a synergistic suppression of signaling that was activated by crosstalk between E2 and growth factors or HER2 amplification. Taken together, our findings suggest that the specific inhibition of BIG3‐PHB2 is a novel potential therapeutic approach for the treatment of tamoxifen‐resistant breast cancers activated by the crosstalk between E2 and growth factor signaling, especially in premenopausal women. 相似文献
999.
Tumor‐suppressive miR‐145 co‐repressed by TCF4‐β‐catenin and PRC2 complexes forms double‐negative regulation loops with its negative regulators in colorectal cancer 下载免费PDF全文
1000.
Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity 下载免费PDF全文
Gary K. Schwartz Mark A. Dickson Patricia M. LoRusso Edward A. Sausville Yoshimi Maekawa Yasuo Watanabe Naomi Kashima Daisuke Nakashima Shiro Akinaga 《Cancer science》2016,107(4):499-506
Numerous solid tumors overexpress or have excessively activated insulin‐like growth factor receptor‐1 (IGF‐1R). We summarize preclinical studies and the first‐in‐human study of KW‐2450, an oral tyrosine kinase inhibitor with IGF‐1R and insulin receptor (IR) inhibitory activity. Preclinical activity of KW‐2450 was evaluated in various in vitro and in vivo models. It was then evaluated in a phase I clinical trial in 13 patients with advanced solid tumors (NCT00921336). In vitro, KW‐2450 inhibited human IGF‐1R and IR kinases (IC50 7.39 and 5.64 nmol/L, respectively) and the growth of various human malignant cell lines. KW‐2450 40 mg/kg showed modest growth inhibitory activity and inhibited IGF‐1‐induced signal transduction in the murine HT‐29/GFP colon carcinoma xenograft model. The maximum tolerated dose of KW‐2450 was 37.5 mg once daily continuously; dose‐limiting toxicity occurred in two of six patients at 50 mg/day (both grade 3 hyperglycemia) and in one of seven patients at 37.5 mg/day (grade 3 rash). Four of 10 evaluable patients showed stable disease. Single‐agent KW‐2450 was associated with modest antitumor activity in heavily pretreated patients with solid tumors and is being further investigated in combination therapy with lapatinib/letrozole in patients with human epidermal growth factor receptor 2‐postive metastatic breast cancer. 相似文献